Form 4: Intellia Therapeutics Director Acquires Stock Options and Restricted Stock Units

Director Frank Verwiel reports acquisition of stock options and restricted stock units in Intellia Therapeutics.

Summary

• On June 12, 2024, Frank Verwiel, a director of Intellia Therapeutics, acquired 7,737 shares of common stock and 11,515 stock options.
• The common stock was acquired at a price of $0.00 per share, representing restricted stock units.
• The stock options have an exercise price of $25.85 and expire on June 11, 2034.
• The stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant.
• Following the transaction, Verwiel directly owns 19,453 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock and options by a director generally signals confidence, but it's a routine filing.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options (either one year from grant date or the next annual meeting) implies continued involvement and alignment with the company's performance.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock and future prospects. The acquisition of shares and options by a director is generally viewed positively.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders, as it signals confidence from a company director.

Key Dates